SCHEMBL7424028

SCHEMBL7424028

CC(=O)c1c(C)[nH]c(C)c1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
HSD17B10 Q99714 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
BRD4 O60885 3/20 0.44
CREBBP Q92793 3/20 0.44
BRPF1 P55201 2/20 0.44
NOTUM Q6P988 1/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 2/20 0.40
NPSR1 Q6W5P4 3/20 0.39
TSHR P16473 1/20 0.39
EP300 Q09472 1/20 0.39
KDM4E B2RXH2 1/20 0.39
KMT2A Q03164 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 2/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL71362 0.89 NOTUM (0.48) CYP1A2CYP3A4HSD17B10SMN1; SMN2BRD4
SCHEMBL29025896 0.89 CYP1A2 (0.61) CYP1A2CYP3A4HSD17B10SMN1; SMN2BRD4
SCHEMBL11584471 0.77 ALDH1A1 (0.52) CYP1A2CYP3A4HSD17B10SMN1; SMN2BRD4
SCHEMBL8145766 0.77 CYP1A2 (0.67) CYP1A2CYP3A4HSD17B10SMN1; SMN2BRD4
SCHEMBL11802081 0.77 NOTUM (0.43) CYP1A2CYP3A4HSD17B10SMN1; SMN2BRD4
SCHEMBL10809246 0.76 CYP1A2 (0.53) CYP1A2CYP3A4HSD17B10SMN1; SMN2BRD4
SCHEMBL1411774 0.75 CYP1A2 (0.76) CYP1A2CYP3A4HSD17B10SMN1; SMN2BRD4
SCHEMBL3285995 0.75 CYP1A2 (0.76) CYP1A2CYP3A4SMN1; SMN2BRD4CREBBP
SCHEMBL7293758 0.75 LMNA (0.56) CYP1A2CYP3A4SMN1; SMN2ALDH1A1MAPT
SCHEMBL5369931 0.73 ALDH1A1 (0.40) CYP1A2CYP3A4HSD17B10SMN1; SMN2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020035127-A1 Phenylalanine derivatives CELLTECH THERAPEUTIS, LIMITED 2002-03-21 US disclosed
US-6329372-B1 HETEROCYCLIC AMIDE COMPOUNDS ARE ABLE TO INHIBIT THE BINDING OF ALPHA4 INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS. CELLTECH THERAPEUTICS LIMITED (GB) 2001-12-11 US disclosed
EP-1051399-A1 PHENYLALANINE DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS CELLTECH THERAPEUTICS LIMITED (GB) 2000-11-15 EP disclosed
WO-1999037618-A1 PHENYLALANINE DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS CELLTECH THERAPEUTICS LIMITED (GB) 1999-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035127-A1 Phenylalanine derivatives PAH, VCAM1, IL4I1 CYP1A2 759/4885CYP3A4 62/4885HSD17B10 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.